ARDX - Ardelyx, Inc.
7.00 0.00 (0.00%)
After hours: 4:53PM EST
| Previous Close | 7.15 |
| Open | 7.15 |
| Bid | 6.86 x 1200 |
| Ask | 7.15 x 1400 |
| Day's Range | 6.86 - 7.16 |
| 52 Week Range | 1.60 - 8.31 |
| Volume | 640,700 |
| Avg. Volume | 844,182 |
| Market Cap | 461M |
| Beta (5Y Monthly) | 1.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.65 |
| Earnings Date | Nov 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.20 |
- Benzinga
The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration of ...
- PR Newswire
Ardelyx Announces Pricing of Upsized Public Offering of Common Stock
Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.25 per share, before underwriting discounts and commissions, for gross proceeds of $125,000,000. In addition, Ardelyx has granted the underwriters of the offering the right for a period of 30 days to purchase up to an additional 3,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about December 9, 2019, subject to customary closing conditions.
- PR Newswire
Ardelyx Announces Proposed Public Offering of Common Stock
Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that it has commenced an underwritten public offering of up to $80,000,000 of shares of its common stock. All shares of common stock to be sold in the offering will be offered by Ardelyx. In addition, Ardelyx intends to grant the underwriters of the offering the right for a period of 30 days to purchase up to an additional $12,000,000 of shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- Benzinga
The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 3) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares ...
- Reuters
UPDATE 2-Ardelyx drug reduces elevated phosphate levels, late-stage study shows
Ardelyx Inc's experimental drug has shown promise in a late-stage study as a standalone therapy to reduce elevated blood phosphate levels in patients with chronic kidney disease (CKD), the drugmaker said on Tuesday. While investor concern is likely over the higher-than-anticipated discontinuation rate, the results were positive with the drug, tenapanor, hitting the key goal of phosphate lowering, Piper Jaffray analyst Christopher Raymond said. The positive results are the latest in a series of wins for Ardelyx.
- PR Newswire
Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis
Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, today reported positive topline results from PHREEDOM, a long-term Phase 3 study evaluating the efficacy and safety of tenapanor as monotherapy for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. In the study, patients randomized to the tenapanor arm were treated in a 26-week open-label treatment period and were then re-randomized to a 12-week double-blind, placebo-controlled randomized withdrawal period. The PHREEDOM study met its primary endpoint demonstrating a statistically significant difference in least square (LS) mean serum phosphorus change (-1.4 mg/dL, p<0.0001), as compared to placebo. During the 26-week treatment period, 77% of tenapanor-treated patients in the intent-to-treat population (n=408) had a decrease in serum phosphorus, with a mean reduction from baseline of 2.0 mg/dL. Tenapanor is an investigational, first-in-class, phosphate absorption inhibitor being developed to treat hyperphosphatemia in patients with CKD on dialysis. If approved, tenapanor will be the only non-binder treatment for the control of serum phosphorus in patients with CKD on dialysis.
- PR Newswire
Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study
Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, announced that it will hold a conference call tomorrow, December 3, at 8:00 am Eastern Time to review the results from the pivotal Phase 3 PHREEDOM study evaluating tenapanor in chronic kidney disease (CKD) patients on dialysis. Tenapanor is Ardelyx's investigational, first-in-class, small molecule, non-binder, phosphate absorption inhibitor.
- Benzinga
The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 26) Allakos Inc (NASDAQ: ALLK ) Alnylam Pharmaceuticals, ...
- PR Newswire
Ardelyx to Present at the Piper Jaffray 31st Annual Healthcare Conference
Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 at 2:00 p.m. ET in New York City.
- Benzinga
The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam ...
- PR Newswire
Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements
Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases and Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based Global Specialty Pharmaceutical Company, today announced the expansion of their partnership with two new agreements.
- PR Newswire
Ardelyx Announces Presentation at Kidney Week 2019
Late breaking oral presentation to highlight data from AMPLIFY, the Pivotal Phase 3 Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment ...
- PR Newswire
Ardelyx Reports Third Quarter 2019 Financial Results and Recent Highlights
PHREEDOM clinical trial to read out this quarter FREMONT, Calif. , Nov. 6, 2019 /PRNewswire/ --Â Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class ...
- Simply Wall St.
Why Ardelyx, Inc.'s (NASDAQ:ARDX) CEO Pay Matters To You
Mike Raab became the CEO of Ardelyx, Inc. (NASDAQ:ARDX) in 2009. This report will, first, examine the CEO compensation...
- PR Newswire
Ardelyx to Host Analyst Day in New York
Management to Review Late Stage Clinical Development and Commercial Potential in Hyperphosphatemia, Pipeline Program in Hyperkalemia and Recent Approval in IBS-C FREMONT, Calif. , Oct. 10, 2019 /PRNewswire/ ...
- Simply Wall St.
Some Ardelyx (NASDAQ:ARDX) Shareholders Have Taken A Painful 73% Share Price Drop
It is doubtless a positive to see that the Ardelyx, Inc. (NASDAQ:ARDX) share price has gained some 93% in the last...
- Zacks
Ironwood Amends Linzess Agreement with AstraZeneca in China
Ironwood (IRWD) announces amendment in collaboration agreement with AstraZeneca, granting the latter exclusive rights to develop, manufacture and commercialize Linzess in China.
- PR Newswire
Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference
FREMONT, Calif., Sept. 17, 2019 /PRNewswire/ --Â Ardelyx, Inc. (ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that Mike Raab, president and chief executive officer of Ardelyx, will present a company overview at the Ladenburg Thalmann Conference on Tuesday, September 24, 2019 at 9:00 a.m. ET in New York City. To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. Ardelyx is focused on enhancing the lives of people with cardiorenal diseases by developing first-in-class medicines that matter.
- Benzinga
A Look At Benzinga Pro's Most-Searched Tickers For September 13, 2019
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Sintx Technologies (NASDAQ: SINT ) shares ...
- Zacks
Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment
Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.
- Zacks
Ardelyx (ARDX) in Focus: Stock Moves 8.3% Higher
Ardelyx (ARDX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
- Benzinga
The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 11) Ardelyx Inc (NASDAQ: ARDX ) Avedro Inc (NASDAQ: AVDR ...
- PR Newswire
Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation
FREMONT, Calif., Sept. 12, 2019 /PRNewswire/ -- Ardelyx, Inc. (ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that the U.S. Food and Drug Administration has approved IBSRELA® (tenapanor), a 50 mg, twice daily oral pill for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. IBSRELA is a minimally-absorbed small molecule that acts locally in the gastrointestinal (GI) tract to inhibit the sodium-hydrogen exchanger NHE3, resulting in an increase in bowel movements and a decrease in abdominal pain for IBS-C patients.
- Benzinga
The Daily Biotech Pulse: Ardelyx Awaits Ruling On Constipation Drug, Double Dose Of Good News For Roche, Tocagen Flunks Brain Cancer Study
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 11.) Avedro Inc (NASDAQ: AVDR ) Catalyst Pharmaceuticals ...
